Who is David Goeddel?

Managing Partner at The Column Group

Where does David Goeddel work?

David Goeddel is Partner Emeritus at The Column Group.

What check size does David Goeddel write?

David Goeddel typically writes checks of $100K – $5M.

What boards does David Goeddel sit on?

David Goeddel holds tracked board seats at A2 Biotherapeutics, Constellation Pharma, Exonics Therapeutics, FLX Bio, FLX Bio, Hexagon Bio, Igenica Biotherapeutics, Neurona Therapeutics, Ngm Biopharmaceuticals, Nurix Therapeutics.

Where did David Goeddel go to school?

David Goeddel studied at University of Colorado Boulder (PhD, Biochemistry); UC San Diego (BA, Chemistry).

David Goeddel

Investor

Partner Emeritus at The Column Group

Burlingame, California

Writes $100K – $5M checks · typically $1.5M

Find your path to David

134 people in our graph share verified history with David — schools, employers, funds. One of them is your warm intro.

Beth SeidenbergunlockedDavid: together at Amgen (2004–2005)

×11David: together at Amgen

Experience

The Column GroupManaging Partnercurrent2006 — present
AmgenSenior VP2004 — 2006
TularikFounder and CEO1991 — 2004
GenentechDirector Molecular Biology1978 — 1993

Skills & more

Technology Transfer14GMP1R&D1Drug Development22Cancer2Drug Discovery31Medicinal ChemistryBiotechnology27Clinical Development5Venture Capital18Oncology4Biochemistry11

+10 more

Due DiligenceTurn Around ManagementTechnology EvaluationVenture FinancingLifesciencesMolecular BiologyBioinformaticsMergersStrategic PlanningPharmaceutical Industry

From David's professional profile.

Deals · 7

A2 BiotherapeuticsBoard seat

via The Column Group · filed Oct 2020 · $71.5M raise

SurrozenBoard seat

via The Column Group · filed Jun 2020 · $50M raise

FLX BioBoard seat

via The Column Group · filed Jun 2019 · $67.1M raise

Exonics TherapeuticsBoard seat

via The Column Group · filed Nov 2018 · $42M raise

Constellation PharmaBoard seat

via The Column Group · filed Dec 2015 · $55.8M raise

Ngm BiopharmaceuticalsBoard seat

via The Column Group · filed Feb 2015 · $60M raise

Igenica BiotherapeuticsBoard seat

via The Column Group · filed Jan 2015 · $6.3M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Hexagon Bio Neurona Therapeutics Nurix Therapeutics

Per SEC Form D filings.

Colleagues at The Column Group

Aadit Shah

Principal at The Column Group

Arnav Mehta, MD, PhD

Venture Partner at The Column Group

Carla Daniel

Partner at The Column Group

Craig Parker

Venture Partner at The Column Group

David V. Goeddel, Ph.D.

General Partner at The Column Group

David V. Goeddel, PhD

Partner Emeritus at The Column Group

Hui Tian

Partner at The Column Group

Hui Tian, PhD

Partner at The Column Group

Network5

Carla Daniel

Partner at The Column Group

Helen Kim

Partner at The Column Group

Hui Tian

Partner at The Column Group

JeenJoo Kang

Venture Partner at The Column Group

Jeff Goater

Partner at The Column Group

Investors connected to David in public investor directories — a warm-intro map.

Frequently asked questions

Who is David Goeddel?: Managing Partner at The Column Group
Where does David Goeddel work?: David Goeddel is Partner Emeritus at The Column Group.
What check size does David Goeddel write?: David Goeddel typically writes checks of $100K – $5M.
What boards does David Goeddel sit on?: David Goeddel holds tracked board seats at A2 Biotherapeutics, Constellation Pharma, Exonics Therapeutics, FLX Bio, FLX Bio, Hexagon Bio, Igenica Biotherapeutics, Neurona Therapeutics, Ngm Biopharmaceuticals, Nurix Therapeutics.
Where did David Goeddel go to school?: David Goeddel studied at University of Colorado Boulder (PhD, Biochemistry); UC San Diego (BA, Chemistry).

Same school

Also attended University of Colorado Boulder327

Steve WozniakCo-founder of Apple Chris RustCo-Founder and Partner at Clear Ventures Sydney EberhardtInvestor at True Ventures Bob ThomasPartner at Oxx Kirsten SuddathInvestor at Next Frontier Capital Carolyn ExarhakisSenior Associate, Legal at JMI Equity

+ 321 more

Also attended UC San Diego446

Elad GilSolo general partner investing through Gil Capital Mark SusterManaging Partner at Upfront Ventures Chester NgGeneral Partner at Atomic BirgitteInvestor at Investinor Houman HaghighiPartner, Business & Corporate Development at Menlo Ventures Freya Svedberg-KeatingInvestor at Medicxi

+ 440 more

Shared employers

Also worked at Amgen102

Parker ConradCo-founder & CEO of Rippling Seth LieblichInvestment Team at 8VC Sean BruichChief Technology Officer at Flare Capital Partners Steph ScottVice President at Questa Capital Beth SeidenbergFounding Managing Director at Westlake Village BioPartners Kelli McKeirnanDirector of Administration at Westlake Village BioPartners

+ 96 more

Also worked at Tularik6

Hui TianPartner at The Column Group Lalo FloresVenture Partner at Scion Life Sciences Monique SchiersingSenior Investment Director at Roche Venture Fund Karl HandelsmanInvestor at Codon Capital Carla DanielPartner at The Column Group Shahid NimjeeCo-founder, Chief Scientific Officer and Stroke Clinical Lead at Basking Biosciences

Also worked at Genentech174

David SchenkeinInvestor at GV (Google Ventures)Karthik ArdhanareeswaranInvestor at GV (Google Ventures)Marco PrunottoInvestor at Medicxi Logan HilleLife Sciences Analyst at CincyTech Josephine ChenInvestor at Sequoia Capital Abbie CelnikerInvestor at Third Rock Ventures

+ 168 more